DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

December 26, 2017
DelMar Pharmaceuticals, Inc.

Supports Lead Program, VAL-083, in Ongoing Clinical Trials  VANCOUVER, British Columbia and MENLO PARK, Calif., Dec. 26, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast … Continue reading DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

December 21, 2017
Qu Biologics Inc.

Vancouver, British Columbia – Dec 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system is pleased to report that they will be presenting clinical outcome data from Qu’s recently completed Phase 2 study in ulcerative colitis at … Continue reading Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

Sirona Biochem Announces Results of AGM & CEO Update

December 20, 2017
Sirona Biochem Corp.

Vancouver, British Columbia – December 19, 2017 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) announces that all resolutions tabled at its Annual General Meeting held on December 18, 2017, were passed. The resolutions included: Fixing the number of directors of the Company at seven; Electing Geraldine Deliencourt-Godefroy, Christopher Hopton, Alex … Continue reading Sirona Biochem Announces Results of AGM & CEO Update

ARTMS PRODUCTS INC. RAISES US$3 MILLION TO ADVANCE A SAFE ALTERNATIVE WAY TO LOCALLY PRODUCE MEDICAL ISOTOPES AND AVOID FUTURE SUPPLY DISRUPTIONS

December 18, 2017
Quark Venture Inc.

Vancouver, British Columbia. – December 18, 2017 – Today, ARTMS Products Inc., the leader in the development of novel technologies which enable the production of the world’s most-used diagnostic imaging isotope, announced it has raised US$3 million. The investment comes from Quark Venture Inc. and GF Securities, through their Global Health Science Fund, which invests in … Continue reading ARTMS PRODUCTS INC. RAISES US$3 MILLION TO ADVANCE A SAFE ALTERNATIVE WAY TO LOCALLY PRODUCE MEDICAL ISOTOPES AND AVOID FUTURE SUPPLY DISRUPTIONS

Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations

December 15, 2017
Aquinox Pharmaceuticals, Inc.

VANCOUVER, British Columbia, Dec. 15, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP) today announced that Lloyd Mackenzie has been promoted, effective immediately, to the newly created position of Chief Operating Officer and Vice President, R&D Operations. “As we focus on executing the clinical development plan for rosiptor, our lead drug candidate, this is … Continue reading Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations

Leading Organizations in the Pacific Northwest Sign MOU for Cascadia Venture Acceleration Network, a Partnership to Fuel Innovation

December 11, 2017

Today, nearly 50 organizations in the Pacific Northwest convened at Cambia Grove in Seattle to sign a memorandum of understanding (MOU) establishing the Cascadia Venture Acceleration Network, a partnership of incubators, accelerators, universities, investors and industry associations that have pledged to work collaboratively in support of entrepreneurs and researchers across British Columbia, Washington state and … Continue reading Leading Organizations in the Pacific Northwest Sign MOU for Cascadia Venture Acceleration Network, a Partnership to Fuel Innovation

Aequus announces the issuance of stock options

December 8, 2017
Aequus Pharmaceuticals Inc.

VANCOUVER, December 8, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the issuance of stock options to directors, officers, staff and consultants.  The stock options give the holders the right to purchase up to … Continue reading Aequus announces the issuance of stock options

Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

 Aquinox Pharmaceuticals, Inc.

Bone, Reproductive, and Urologic Drugs Advisory Committee Votes Unanimously  in Favor of Unified IC/BPS Population for Clinical Trials – SILVER SPRING, Md., Dec. 07, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox“) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today issued the following statements following the U.S. Food … Continue reading Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

NASA Research Announcement (NRA) 80JSC017N0001-BPBA – Topics in Biological, Physiological, and Behavioral Adaptations to Spaceflight: Integrated One Year Mission Project and Other Opportunities

December 6, 2017
Canadian Space Agency

The Canadian Space Agency (CSA) would like to inform the Canadian Health and Biomedical community of the release of a NASA Research Announcement (NRA). NASA’s Human Research Program (HRP) released Appendix C of the Human Exploration Research Opportunities (HERO) NRA on November 30, 2017. This NASA Research Announcement solicits proposals to study International Space Station … Continue reading NASA Research Announcement (NRA) 80JSC017N0001-BPBA – Topics in Biological, Physiological, and Behavioral Adaptations to Spaceflight: Integrated One Year Mission Project and Other Opportunities

Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting

December 5, 2017
Xenon Pharmaceuticals Inc.

Data Suggest Xenon’s Selective Nav1.6 Sodium Channel Inhibitor, XEN901, Provides Efficacy with a Potentially Improved Safety Profile over Other Non-Selective, Sodium Channel Blocker Anti-Epileptic Drugs (AEDs) BURNABY, British Columbia, Dec. 04, 2017 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced the presentation of a scientific poster entitled “Selective Inhibitors Suggest Nav1.6 … Continue reading Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting